Fibronectin extradomain A: balancing atherosclerotic plaque burden and stability

Insight on Pulakazhi Venu et al. Thromb Haemost 2015; 114: 186–197.

• References

• 1 Rohwedder I, Montanez E, Beckmann K. et al. Plasma fibronectin deficiency impedes atherosclerosis progression and fibrous cap formation. EMBO Mol Med 2012; 04: 564-576.
• 2 Babaev VR, Porro F, Linton MF. et al. Absence of regulated splicing of fibronectin EDA exon reduces atherosclerosis in mice. Atherosclerosis 2008; 197: 534-540.
• 3 Pulakazhi Venu VK, Uboldi P, Dhyani A. et al. Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice. Thromb Haemost 2015; 114: 186-197.
• 4 van Keulen JK, de Kleijn DP, Nijhuis MMO. et al. Levels of extra domain A containing fibronectin in human atherosclerotic plaques are associated with a stable plaque phenotype. Atherosclerosis 2007; 195: e83-91.
• 5 Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17: 1410-1422.